Does Regence Cover Dupixent? A Detailed Insurance Guide

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathway, two cytokines that drive type 2 inflammatory disease. The FDA has approved dupilumab for moderate-to-severe atopic dermatitis in patients as young as 6 months, moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, and, as of 2024, moderate-to-severe COPD with a type 2 inflammatory phenotype. [1]

Because Dupixent's list price sits near $44,000 per year, insurers including Regence place it on a specialty tier and build formal review processes around it. Getting coverage approved is entirely possible, but it takes preparation.

How Regence Classifies Dupixent on Its Formulary

Regence plans typically list dupilumab as a specialty-tier biologic, which is the highest formulary tier on most plans. That classification matters for two reasons. First, it triggers a prior authorization (PA) requirement before the pharmacy or specialty pharmacy will dispense the drug. Second, it places dupilumab in a cost-sharing bracket that carries a coinsurance percentage rather than a flat copay, meaning your share scales with the drug's price.

Regence operates distinct formularies for its commercial, Medicare Advantage, and Medicaid (Coordinated Care) lines of business, so the exact tier and criteria differ by plan. Always pull the Summary of Benefits and Coverage (SBC) and the drug-specific medical policy document for your specific plan year.

What "Prior Authorization" Actually Means at Regence

A prior authorization is a written clinical review that your prescribing physician initiates before treatment starts. Regence's specialty pharmacy team or a contracted pharmacy benefit manager (PBM) reviews the submission against published clinical criteria. For dupilumab, those criteria typically require: a confirmed diagnosis that matches an FDA-approved indication, documentation of disease severity, and evidence that at least one first-line therapy has been tried and failed or is contraindicated. Approval periods are usually 12 months, after which your physician must submit a renewal PA.

FDA-Approved Indications Regence Typically Covers

Regence aligns coverage criteria with FDA labeling, which is the most important baseline to know. Off-label use of dupilumab is almost never covered without an extraordinary exception process.

Atopic Dermatitis

The SOLO-1 and SOLO-2 trials (combined N = 1,379) demonstrated that dupilumab 300 mg every two weeks produced an IGA score of 0 or 1 (clear or almost clear skin) in 36 to 38 percent of adults at 16 weeks, compared with 8 to 10 percent for placebo (P<0.0001). [2] The LIBERTY AD CHRONOS trial (N = 740) extended those results to 52 weeks with similar safety. [3]

Regence medical policies for atopic dermatitis PA typically require:

• A diagnosis of moderate-to-severe AD confirmed by a dermatologist or allergist
• An IGA score of 3 or 4 (or EASI score above a defined threshold)
• Documented failure of at least a 3-month trial of a topical corticosteroid (TCS) of medium-to-high potency, and failure or contraindication of systemic immunosuppressants such as cyclosporine, methotrexate, or azathioprine in adults (step therapy requirements are more limited in pediatric patients)

Moderate-to-Severe Asthma

The LIBERTY ASTHMA QUEST trial (N = 1,902) showed dupilumab 200 mg every two weeks reduced annualized severe exacerbation rates by 47.7 percent versus placebo in patients with a baseline blood eosinophil count of 150 cells per microliter or higher (P<0.001). [4] Regence PA criteria for asthma generally require an eosinophil count above a specified threshold (often 150 to 300 cells per microliter) plus documented inadequate control on medium-to-high-dose inhaled corticosteroids plus a long-acting beta agonist.

CRSwNP, EoE, and Prurigo Nodularis

The SINUS-24 and SINUS-52 trials established dupilumab's efficacy in CRSwNP, with significant reductions in nasal polyp score and nasal congestion. [5] For EoE, the LIBERTY EoE TREET trial (N = 239) showed dupilumab 300 mg weekly produced histologic remission (peak eosinophil count <6 per high-power field) in 59.5 percent of patients at 24 weeks versus 5.9 percent for placebo. [6] Prurigo nodularis coverage follows the FDA's 2022 approval and typically requires a dermatologist-documented diagnosis with inadequate response to topical therapies.

COPD (Type 2 Inflammatory Phenotype)

The BOREAS trial (N = 939) reported that dupilumab 300 mg every two weeks reduced the annualized rate of moderate-to-severe COPD exacerbations by 30 percent versus placebo (rate ratio 0.70, P<0.001) in patients with a blood eosinophil count of 300 cells per microliter or higher. [7] Coverage for this indication is newer; expect Regence to require subspecialist documentation and eosinophil lab values in the PA submission.

How to Get Dupixent Approved Through Regence

Getting a PA approved is a clinical and administrative process. These are the concrete steps your care team should follow.

Step 1: Confirm Your Plan's Medical Policy Document

Call the member services number on the back of your Regence ID card and ask the representative to send you the current medical policy for dupilumab (policy numbers vary by plan year). You can also search Regence's online medical policy library. Read the criteria carefully before your physician's office submits the PA, because a mismatched or incomplete submission is the single most common reason for denial.

Step 2: Gather the Required Clinical Documentation

Your prescribing physician's office will need to compile:

• Office visit notes confirming diagnosis and severity scoring (IGA, EASI, ACQ, NPS, or relevant disease index)
• Lab results (blood eosinophil count for asthma or COPD indications)
• A dated medication history showing prior therapies, dosages, durations, and reasons for discontinuation
• Photographs (for skin indications, some plans request them)
• A letter of medical necessity signed by the prescribing physician

The letter of medical necessity is worth special attention. It should cite the specific Regence medical policy criteria by name, map each criterion to the patient's chart data, and include a sentence explaining why the requested therapy is medically appropriate for this individual patient. A generic template letter rarely survives PA review intact.

Step 3: Submit and Track the PA Request

Regence accepts PA submissions by fax, through the Regence provider portal, or through electronic PA platforms such as CoverMyMeds. The statutory turnaround for standard PA requests is 14 days under most state laws; urgent (expedited) requests must be answered within 72 hours. Washington, Oregon, Idaho, and Utah each have state prompt-pay and PA timeline laws that apply to Regence plans, so check state-specific timelines if your case is time-sensitive.

Step 4: If Denied, File an Appeal Immediately

A PA denial is not the end of the road. Under the Affordable Care Act and applicable state law, Regence members have the right to an internal appeal and, if that fails, an independent external review. In the LIBERTY-AD trial program, dupilumab's efficacy data are substantial, and a well-constructed appeal citing peer-reviewed evidence and your physician's specific clinical rationale succeeds in a meaningful proportion of cases. Ask your physician's office to submit a peer-to-peer review request with a Regence medical director as part of the internal appeal; that direct conversation often resolves denials faster than written appeals alone.

What Dupixent Will Cost You After Approval

Coverage approval does not mean zero cost. Understanding your cost-sharing structure is equally important.

Specialty Tier Cost-Sharing on Regence Plans

Specialty-tier drugs on Regence commercial plans typically carry a coinsurance of 20 to 33 percent after the deductible is met. On a drug with a list price near $3,700 per month, 20 percent coinsurance translates to roughly $740 per month before any assistance programs apply. Your out-of-pocket maximum caps total annual spending, but that cap can be $3,000 to $8,700 or higher depending on your plan.

Sanofi's Dupixent MyWay Copay Program

Sanofi offers the Dupixent MyWay program for commercially insured patients who meet eligibility requirements. Eligible patients may pay as little as $0 per month, with a maximum benefit of up to $13,000 per calendar year. Patients on government insurance (Medicare, Medicaid, TRICARE) are not eligible for the copay card. To enroll, visit the Dupixent MyWay website or call 1-844-DUPIXENT. Your specialty pharmacy coordinator can often handle enrollment on your behalf.

Patient Assistance for Uninsured or Underinsured Patients

Patients who have no insurance or who are denied coverage may apply to Sanofi's patient assistance program (Dupixent MyWay Patient Assistance Program), which provides the drug at no cost to qualifying low-income patients. Income thresholds and documentation requirements apply.

Medicare Advantage and Dupixent: Regence Special Considerations

Regence administers Medicare Advantage plans in its service states. Medicare Part D formularies for dupilumab vary by plan year and region. As of 2025, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D enrollees applies to specialty drugs, which significantly reduces the financial burden for Regence Medicare Advantage members who have dupilumab approved. Check your plan's Annual Notice of Change (ANOC) each fall to confirm the current tier placement and step therapy requirements.

Step Therapy: The Biggest Barrier and How to Overcome It

Step therapy (sometimes called "fail first") is the most common structural barrier to dupilumab approval at Regence. The plan requires documented failure of cheaper, conventional therapies before authorizing the biologic.

The following decision framework reflects the approach HealthRX's clinical team recommends when counseling patients navigating Regence's step therapy requirements for dupilumab:

Tier 1 (must document failure first): High-potency topical corticosteroids for at least 3 months for AD; medium-to-high-dose ICS plus LABA for asthma; intranasal corticosteroids for CRSwNP.

Tier 2 (often required for adult AD): At least one systemic immunosuppressant trial (cyclosporine, methotrexate, mycophenolate, or azathioprine) of adequate dose and duration, or documented contraindication to each.

Exemption triggers: Active or recent malignancy, pregnancy, severe hepatotoxicity risk from systemic agents, or a specialist's documented clinical judgment that step therapy poses unacceptable risk.

State step therapy protection laws matter here. Washington state's step therapy reform law (RCW 48.43.700) requires insurers, including Regence, to grant a step therapy exception when the required drug is contraindicated, has been tried and failed previously, or when a patient is stable on a biologic and switching would cause harm. Oregon and Idaho have comparable protections. If your physician documents that conventional therapy is medically inappropriate for your patient, Regence must accept that documentation under these laws.

The American Academy of Dermatology's Atopic Dermatitis guidelines state directly: "Dupilumab is recommended for patients with moderate-to-severe AD who are candidates for systemic therapy." [8] Citing guideline language in an appeal letter positions dupilumab not as an optional luxury but as guideline-concordant care.

Regence Coverage for Pediatric Patients

Dupilumab is FDA-approved for atopic dermatitis starting at 6 months of age, with weight-based dosing schedules for children under 6 years. Regence pediatric PA criteria generally align with FDA labeling but may require documentation from a board-certified pediatric dermatologist or allergist rather than a general practitioner. Step therapy requirements for children are often less extensive than for adults, partly because systemic immunosuppressants carry a higher risk profile in pediatric patients.

For pediatric asthma, dupilumab is approved down to age 6 for add-on maintenance therapy. The LIBERTY ASTHMA VOYAGE trial in children aged 6 to 11 (N = 408) showed a 65 percent reduction in annualized severe exacerbation rates versus placebo (P<0.001). [9] Include this trial data when constructing a pediatric asthma PA or appeal submission for Regence.

Practical Tips From the HealthRX Clinical Team

A few concrete actions improve your odds of first-pass PA approval significantly.

Use a specialty pharmacy that Regence contracts with preferentially. Regence often routes specialty biologics through a preferred specialty pharmacy network (commonly Accredo or CVS Specialty depending on the PBM). Using an out-of-network specialty pharmacy can result in higher cost-sharing even if the drug is covered.

Ask your physician to submit the PA and the letter of medical necessity simultaneously rather than waiting for the initial submission to be reviewed. This reduces round-trip delays.

Keep a dated file of all prior therapy records going back at least two years. PA reviewers reject submissions that reference prior therapy failures without specific dates, dosages, and documented adverse events or inadequate responses.

If your plan's PBM is Express Scripts, note that Dupixent has historically been listed as covered on the ESI formulary for Regence-administered plans, though tier placement and criteria still apply.

Dr. Jonathan Silverberg, a board-certified dermatologist and atopic dermatitis researcher at George Washington University, has stated publicly: "For patients with moderate-to-severe atopic dermatitis who have failed topical therapies, dupilumab represents the standard of care, and delays in access due to administrative barriers directly translate to ongoing disease burden and reduced quality of life." That framing, supported by published clinical data, is exactly the argument that belongs in a Regence appeal letter.

Frequently Asked Questions